Logo image of NKTR

NEKTAR THERAPEUTICS (NKTR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NKTR - US6402683063 - Common Stock

43.51 USD
+0.54 (+1.26%)
Last: 1/7/2026, 8:00:01 PM
43.51 USD
0 (0%)
After Hours: 1/7/2026, 8:00:01 PM
Fundamental Rating

3

NKTR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for NKTR as it has an excellent financial health rating, but there are worries on the profitability. NKTR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NKTR had negative earnings in the past year.
In the past year NKTR has reported a negative cash flow from operations.
NKTR had negative earnings in each of the past 5 years.
NKTR had a negative operating cash flow in each of the past 5 years.
NKTR Yearly Net Income VS EBIT VS OCF VS FCFNKTR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

1.2 Ratios

NKTR has a Return On Assets (-40.07%) which is comparable to the rest of the industry.
NKTR's Return On Equity of -141.90% is on the low side compared to the rest of the industry. NKTR is outperformed by 70.16% of its industry peers.
Industry RankSector Rank
ROA -40.07%
ROE -141.9%
ROIC N/A
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
NKTR Yearly ROA, ROE, ROICNKTR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

With an excellent Gross Margin value of 87.26%, NKTR belongs to the best of the industry, outperforming 89.53% of the companies in the same industry.
NKTR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NKTR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.26%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
NKTR Yearly Profit, Operating, Gross MarginsNKTR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

7

2. Health

2.1 Basic Checks

NKTR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NKTR has less shares outstanding
NKTR has more shares outstanding than it did 5 years ago.
NKTR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NKTR Yearly Shares OutstandingNKTR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
NKTR Yearly Total Debt VS Total AssetsNKTR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

NKTR has an Altman-Z score of -15.31. This is a bad value and indicates that NKTR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NKTR (-15.31) is worse than 79.06% of its industry peers.
NKTR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.31
ROIC/WACCN/A
WACC9.44%
NKTR Yearly LT Debt VS Equity VS FCFNKTR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 4.24 indicates that NKTR has no problem at all paying its short term obligations.
NKTR has a Current ratio of 4.24. This is in the better half of the industry: NKTR outperforms 60.73% of its industry peers.
A Quick Ratio of 4.24 indicates that NKTR has no problem at all paying its short term obligations.
The Quick ratio of NKTR (4.24) is better than 62.83% of its industry peers.
Industry RankSector Rank
Current Ratio 4.24
Quick Ratio 4.24
NKTR Yearly Current Assets VS Current LiabilitesNKTR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

2

3. Growth

3.1 Past

NKTR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 14.13%, which is quite good.
Looking at the last year, NKTR shows a very negative growth in Revenue. The Revenue has decreased by -32.79% in the last year.
The Revenue has been decreasing by -3.00% on average over the past years.
EPS 1Y (TTM)14.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.74%
Revenue 1Y (TTM)-32.79%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%-51.13%

3.2 Future

The Earnings Per Share is expected to decrease by -0.28% on average over the next years.
NKTR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.92% yearly.
EPS Next Y9.43%
EPS Next 2Y6.75%
EPS Next 3Y-0.17%
EPS Next 5Y-0.28%
Revenue Next Year-56.1%
Revenue Next 2Y-35.01%
Revenue Next 3Y-29.51%
Revenue Next 5Y3.92%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NKTR Yearly Revenue VS EstimatesNKTR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
NKTR Yearly EPS VS EstimatesNKTR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 20 -20 40 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NKTR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NKTR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NKTR Price Earnings VS Forward Price EarningsNKTR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NKTR Per share dataNKTR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.75%
EPS Next 3Y-0.17%

More info and screens

0

5. Dividend

5.1 Amount

NKTR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

NEKTAR THERAPEUTICS

NASDAQ:NKTR (1/7/2026, 8:00:01 PM)

After market: 43.51 0 (0%)

43.51

+0.54 (+1.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-10 2026-03-10/amc
Inst Owners71.23%
Inst Owner Change0%
Ins Owners0.84%
Ins Owner Change0.53%
Market Cap884.99M
Revenue(TTM)62.60M
Net Income(TTM)-120.74M
Analysts85.71
Price Target116.72 (168.26%)
Short Float %9.54%
Short Ratio2.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.21%
Min EPS beat(2)4.71%
Max EPS beat(2)31.71%
EPS beat(4)3
Avg EPS beat(4)-0.01%
Min EPS beat(4)-43.22%
Max EPS beat(4)31.71%
EPS beat(8)5
Avg EPS beat(8)-0.46%
EPS beat(12)7
Avg EPS beat(12)-0.71%
EPS beat(16)11
Avg EPS beat(16)4.27%
Revenue beat(2)2
Avg Revenue beat(2)8.01%
Min Revenue beat(2)0.98%
Max Revenue beat(2)15.04%
Revenue beat(4)2
Avg Revenue beat(4)-5.38%
Min Revenue beat(4)-33.31%
Max Revenue beat(4)15.04%
Revenue beat(8)6
Avg Revenue beat(8)13.39%
Revenue beat(12)8
Avg Revenue beat(12)9.53%
Revenue beat(16)9
Avg Revenue beat(16)6.67%
PT rev (1m)21.92%
PT rev (3m)10.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.2%
EPS NY rev (1m)0.09%
EPS NY rev (3m)12.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.14
P/FCF N/A
P/OCF N/A
P/B 10.4
P/tB 10.4
EV/EBITDA N/A
EPS(TTM)-10.82
EYN/A
EPS(NY)-10.07
Fwd EYN/A
FCF(TTM)-9.36
FCFYN/A
OCF(TTM)-9.33
OCFYN/A
SpS3.08
BVpS4.18
TBVpS4.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.07%
ROE -141.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.26%
FCFM N/A
ROA(3y)-53.44%
ROA(5y)-47.22%
ROE(3y)-169.02%
ROE(5y)-125.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y-3.28%
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.4%
Cap/Sales 0.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.24
Quick Ratio 4.24
Altman-Z -15.31
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)29.45%
Cap/Depr(5y)49.23%
Cap/Sales(3y)2.88%
Cap/Sales(5y)5.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.74%
EPS Next Y9.43%
EPS Next 2Y6.75%
EPS Next 3Y-0.17%
EPS Next 5Y-0.28%
Revenue 1Y (TTM)-32.79%
Revenue growth 3Y-1.15%
Revenue growth 5Y-3%
Sales Q2Q%-51.13%
Revenue Next Year-56.1%
Revenue Next 2Y-35.01%
Revenue Next 3Y-29.51%
Revenue Next 5Y3.92%
EBIT growth 1Y-0.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.36%
EBIT Next 3Y-31.32%
EBIT Next 5YN/A
FCF growth 1Y6.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.67%
OCF growth 3YN/A
OCF growth 5YN/A

NEKTAR THERAPEUTICS / NKTR FAQ

What is the fundamental rating for NKTR stock?

ChartMill assigns a fundamental rating of 3 / 10 to NKTR.


What is the valuation status for NKTR stock?

ChartMill assigns a valuation rating of 0 / 10 to NEKTAR THERAPEUTICS (NKTR). This can be considered as Overvalued.


Can you provide the profitability details for NEKTAR THERAPEUTICS?

NEKTAR THERAPEUTICS (NKTR) has a profitability rating of 1 / 10.